A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
Hospital Central de Asturias, Oviedo, Asturias, Spain
Hospital general de Castellón, Castello, Castellón, Spain
Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain
Hospital Sant Pau, Barcelona, Spain
Hospital Ntra. Sra. de Sonsoles, Avila, Spain
Hosptal Joan XXIII, Tarragona, Spain
Hospital Germans Trias i Pujol, Badalona, Spain
Hospital Universitario La Paz, Madrid, Spain
Hospital del Mar, Barcelona, Spain
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
UT MD Anderson Cancer Center, Houston, Texas, United States
University Health Network, Toronto, Ontario, Canada
M D Anderson Cancer Center, Houston, Texas, United States
Ohio State University Medical Center, Columbus, Ohio, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Children's Hospital of Boston, Boston, Massachusetts, United States
UT MD Anderson Cancer Center, Houston, Texas, United States
UT MD Anderson Cancer Center, Houston, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.